Cleerly will demonstrate its FDA-cleared heart image analyses using mobile scanners in collaboration with Corazon Imaging and Philips

CHICAGO: #AI--Cleerly, a leader in AI imaging technology, is proud to support the American College of Cardiology’s (ACC) Chicago Community Health Fair. This event will take place on Tuesday, March 25, from 3-7 p.m. CT at The Salvation Army Ray & Joan Kroc Corps Community Center.

Heart disease is the leading cause of death in the U.S. and worldwide. The event aims to promote heart health as an accessible and equitable resource for all community members. Attendees will learn about actionable strategies that can improve heart health, including guidance on exercise, healthy eating, and medical interventions. Additionally, the event will feature on-site heart screenings for blood pressure and heart murmurs, as well as informative sessions about heart disease.

In collaboration with local Chicago doctors and Corazon Imaging, Cleerly is providing advanced AI-Quantitative Coronary CT (AI-QCT) analyses for coronary atherosclerotic plaque to patients from the community. Coronary atherosclerotic plaque is a buildup within artery walls that narrows and restricts blood flow to the heart muscle and can lead to cardiovascular complications, including heart attacks. Local doctors will explain the findings to patients and advise them on actionable strategies that can improve heart health.

Just as mammograms are used for early cancer detection, Cleerly uses an AI-enabled platform to analyze advanced imaging to assist in the early identification of patients at higher risk for heart attacks. Along with receiving FDA clearance, Cleerly is also a covered service for Medicare, a status that requires robust clinical support and evidence.

“We understand what a clear diagnosis and a personalized treatment plan can do for someone’s peace of mind and heart health, and we have made it our mission to identify at-risk individuals before a heart attack occurs,” said James Min, MD, founder and CEO of Cleerly. “Along with our partners and the amazing doctors of Chicago, we are thrilled to bring Cleerly’s AI-based Plaque and Ischemia software to the ACC’s Chicago Community Health Fair.”

"While Coronary CTA's role as a frontline tool to diagnose coronary artery disease has been a long time coming, it is absolutely here to stay. While initially valuable at determining coronary artery stenoses, CCTA has rapidly evolved to provide comprehensive information about plaque type, burden, and hemodynamic significance. Corazon has demonstrated this diagnostic pathway can be effectively translated to the community-based setting with over 8,000 CCTAs performed to date," said John Rumberger, PhD, MD, FACC, MSCCT, Medical Director and Director of Cardiac Imaging at Corazon Imaging.

“Philips is dedicated to providing better care for more people. With cardiovascular disease on the rise, the ability to bring wider access to high-quality cardiac care directly to communities can be impactful,” said Melissa Howard, CT Business Leader, Philips North America. “Corazon Imaging’s mobile CT unit, which will be at ACC’s Chicago Community Health Fair, features the Philips CT 5100 Incisive. Using Philips’ latest AI-enabled technology to get clear images with less radiation exposure means patients can get accurate diagnoses faster and with more confidence.”

The Chicago Community Health Fair is part of the ACC’s broader 2025 Annual Scientific Session, which will gather the global cardiovascular community in Chicago from March 29-31.

Learn More

Visit www.cleerlyhealth.com to learn more about Cleerly and find a provider near you. For additional information about coronary artery disease, visit our education page: https://cleerlyhealth.com/patient-education.

About Cleerly

Cleerly is the company on a mission to eliminate heart attacks by creating a new standard of care for heart disease. Through its FDA-cleared solutions driven by artificial intelligence, Cleerly supports comprehensive phenotyping of coronary artery disease, as determined from advanced noninvasive CT imaging. Cleerly’s approach is grounded in science, based on millions of images from over 40,000 patients. Led by a world-class clinical and technical team, Cleerly enhances health literacy for each and every stakeholder in the coronary care pathway. For more information, please visit: cleerlyhealth.com.

Fonte: Business Wire